VIRAX BIOLABS GROUP LTD (VRAX) Stock Fundamental Analysis

NASDAQ:VRAX • KYG9495L1251

0.2277 USD
+0.01 (+3.03%)
At close: Feb 27, 2026
0.2277 USD
0 (0%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

VRAX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. VRAX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VRAX is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year VRAX has reported negative net income.
  • VRAX had a negative operating cash flow in the past year.
  • VRAX had negative earnings in each of the past 5 years.
  • In the past 5 years VRAX always reported negative operating cash flow.
VRAX Yearly Net Income VS EBIT VS OCF VS FCFVRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M

1.2 Ratios

  • With a Return On Assets value of -98.75%, VRAX is not doing good in the industry: 93.07% of the companies in the same industry are doing better.
  • The Return On Equity of VRAX (-106.24%) is worse than 77.23% of its industry peers.
Industry RankSector Rank
ROA -98.75%
ROE -106.24%
ROIC N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRAX Yearly ROA, ROE, ROICVRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VRAX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRAX Yearly Profit, Operating, Gross MarginsVRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VRAX has been increased compared to 1 year ago.
  • Compared to 5 years ago, VRAX has less shares outstanding
  • The debt/assets ratio for VRAX is higher compared to a year ago.
VRAX Yearly Shares OutstandingVRAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VRAX Yearly Total Debt VS Total AssetsVRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

  • Based on the Altman-Z score of 1.16, we must say that VRAX is in the distress zone and has some risk of bankruptcy.
  • VRAX has a worse Altman-Z score (1.16) than 65.35% of its industry peers.
  • A Debt/Equity ratio of 0.09 indicates that VRAX is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.09, VRAX is doing good in the industry, outperforming 75.25% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 1.16
ROIC/WACCN/A
WACC11.06%
VRAX Yearly LT Debt VS Equity VS FCFVRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 11.35 indicates that VRAX has no problem at all paying its short term obligations.
  • VRAX has a better Current ratio (11.35) than 98.02% of its industry peers.
  • VRAX has a Quick Ratio of 11.20. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 11.20, VRAX belongs to the top of the industry, outperforming 98.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.35
Quick Ratio 11.2
VRAX Yearly Current Assets VS Current LiabilitesVRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • VRAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.89%, which is quite impressive.
  • Looking at the last year, VRAX shows a very negative growth in Revenue. The Revenue has decreased by -96.47% in the last year.
  • Measured over the past years, VRAX shows a very negative growth in Revenue. The Revenue has been decreasing by -42.47% on average per year.
EPS 1Y (TTM)51.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.72%
Revenue 1Y (TTM)-96.47%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-68%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • Based on estimates for the next years, VRAX will show a quite strong growth in Revenue. The Revenue will grow by 16.04% on average per year.
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRAX Yearly Revenue VS EstimatesVRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5M 10M 15M 20M 25M
VRAX Yearly EPS VS EstimatesVRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 5.58, the valuation of VRAX can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, VRAX is valued cheaper than 97.03% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of VRAX to the average of the S&P500 Index (28.06), we can say VRAX is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.58
VRAX Price Earnings VS Forward Price EarningsVRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRAX Per share dataVRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • VRAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VIRAX BIOLABS GROUP LTD

NASDAQ:VRAX (2/27/2026, 8:00:02 PM)

After market: 0.2277 0 (0%)

0.2277

+0.01 (+3.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A
Earnings (Next)12-13
Inst Owners6.97%
Inst Owner ChangeN/A
Ins Owners5.64%
Ins Owner ChangeN/A
Market Cap1.69M
Revenue(TTM)3.00K
Net Income(TTM)-5.64M
Analysts82.86
Price Target1.02 (347.96%)
Short Float %0.92%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-95%
PT rev (3m)-95%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.58
P/S 563.18
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.32
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)0.04
Fwd EY17.92%
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0
BVpS0.72
TBVpS0.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -98.75%
ROE -106.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.9%
ROA(5y)-1063.54%
ROE(3y)-97.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.76%
Cap/Sales 16580%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.35
Quick Ratio 11.2
Altman-Z 1.16
F-Score1
WACC11.06%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)4134.9%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.72%
EPS Next Y166.67%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-96.47%
Revenue growth 3YN/A
Revenue growth 5Y-42.47%
Sales Q2Q%-68%
Revenue Next Year66.97%
Revenue Next 2Y-29.64%
Revenue Next 3Y-4.67%
Revenue Next 5Y16.04%
EBIT growth 1Y6.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year161.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.95%
OCF growth 3YN/A
OCF growth 5YN/A

VIRAX BIOLABS GROUP LTD / VRAX FAQ

Can you provide the ChartMill fundamental rating for VIRAX BIOLABS GROUP LTD?

ChartMill assigns a fundamental rating of 3 / 10 to VRAX.


What is the valuation status for VRAX stock?

ChartMill assigns a valuation rating of 4 / 10 to VIRAX BIOLABS GROUP LTD (VRAX). This can be considered as Fairly Valued.


Can you provide the profitability details for VIRAX BIOLABS GROUP LTD?

VIRAX BIOLABS GROUP LTD (VRAX) has a profitability rating of 0 / 10.